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Abstract
Background: Evidence shows that territorial borders continue to have an impact on research collaboration in
Europe. Knowledge of national research structural contexts is therefore crucial to the promotion of Europe-wide
policies for research funding. Nevertheless, studies assessing and comparing research systems remain scarce. This
paper aims to further the knowledge on national research landscapes in Europe, focusing on non-communicable
disease (NCD) research in Italy and Germany.
Methods: To capture the architecture of country-specific research funding systems, a three-fold strategy was
adopted. First, a literature review was conducted to determine a list of key public, voluntary/private non-profit and
commercial research funding organisations (RFOs). Second, an electronic survey was administered qualifying RFOs.
Finally, survey results were integrated with semi-structured interviews with key opinion leaders in NCD research.
Three major dimensions of interest were investigated – funding mechanisms, funding patterns and expectations
regarding outputs.
Results: The number of RFOs in Italy is four times larger than that in Germany and the Italian research system has
more project funding instruments than the German system. Regarding the funding patterns towards NCD areas, in
both countries, respiratory disease research resulted as the lowest funded, whereas cancer research was the target
of most funding streams. The most reported expected outputs of funded research activity were scholarly publication of
articles and reports.
Conclusions: This cross-country comparison on the Italian and German research funding structures revealed
substantial differences between the two systems. The current system is prone to duplicated research efforts,
popular funding for some diseases and intransparency of research results. Future research will require addressing
the need for better coordination of research funding efforts, even more so if European research efforts are to play
a greater role.
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Background
Research investments in Europe have shown an increase
in the past years, with the expenditure for research and
development, as a percentage of gross domestic product,
having grown from 1.8% to 2.0% between 2002 and
2014, although still falling short of the 3% target set
under the Europe 2020 strategy [1]. Biomedical, and
more specifically, non-communicable disease (NCD) re-
search funding show cross-country differences in struc-
tures and funding amounts, and there is still a long way
to go towards an integration of research efforts across
the European Union [2]. In fact, studies show that terri-
torial borders, both political and language-related, con-
tinue to have an impact on research collaboration in
Europe [3]. Knowledge of national research structural
contexts is therefore crucial to the promotion of
Europe-wide policies for research funding. Nevertheless,
characteristics of national research systems that drive
funding decision and research outcomes are not well
understood and the expertise to navigate through na-
tional research landscapes scarcely travels from one
country to another. This paper aims to deepen the
knowledge on national funding systems for biomedical
research, with a focus on NCDs in Europe, taking into
consideration two national case studies, Italy and
Germany. Both are major European Union continental
countries that nevertheless differentiate in terms of their
healthcare system and biomedical research.
Germany operates a Statutory Health Insurance sys-
tem, which is mainly funded through contributions from
employers and employees. In Italy, the National Health
Service provides universal coverage and is funded through
general taxation and, in smaller part, through user
charges. In terms of biomedical research systems, both
countries have a track record of excellence and inter-
nationally recognised work, albeit with some differences
in the approach to research funding (e.g. higher level of
private and industry-funded research activities in
Germany). Therefore, the Italian and German research
systems appear to be a good match to understand the
multilevel framework of research funding, its funding pat-
terns, and its mechanisms and actors.
Methods
Definitions
This article builds on the findings of the project
MAPPING_NCD (grant agreement #602536), a 2-year
project funded by the European Commission under the
7th framework programme, that aimed to draw a map of
European research funding for five NCD areas in order
to develop evidence-based policies for future research.
NCDs are defined as diseases that are not passed from
person to person and are of chronic nature [4]. The
NCD areas considered herein are cardiovascular
diseases, chronic respiratory diseases, mental health
diseases, diabetes and cancer. A previous publication
provides details on the mixed methods approach, com-
bining qualitative and quantitative data, employed
throughout the project [5]. An inclusive definition of
‘research’ that encompasses basic, clinical, policy and
management research was adopted in this analysis.
Study design
This mixed-method study uses a case-oriented approach
[6] to describe the NCD research funding systems in
Italy and Germany. The comparative research design is a
two-country comparison, which is often associated with
mixed methodologies [7], as employed in the analysis of
the two country-specific systems. Similarly to a study
conducted by Viergever and Hendriks [8] on public and
philanthropic institutions funding health research glo-
bally, three dimensions were considered, namely identifi-
cation of the network of research funding organisations
(RFOs), assessment of funding patterns and funding dis-
tribution mechanisms in Italy and Germany.
Data collection methods
To capture the architecture of country-specific research
funding systems with a broad-based view, three steps were
used. First, a non-systematic literature review was con-
ducted to determine a list of key public, voluntary/private
non-profit and commercial RFOs at national level and their
funding practices in biomedical research, with focus on
NCD-related projects. PubMed and Google scholar were
searched for relevant articles based on disease-specific key-
words (e.g. ‘diabetes’, ‘funding’ combined with ‘Italy’). Sec-
ond, an electronic survey was administered to qualify
funding by individual RFOs, defined as those funding
NCD-related research activities worth at least €0.5 million
during the period 2002–2013, as determined by analysis of
public financial statements released by the organisations.
This threshold was set in order to select organisations play-
ing a relatively significant role in shaping the research
stream within particular disease areas. The survey was de-
signed using Qualtrics® (Provo, UT) and translated in the
national language to encourage RFO participation [5].
Contact with RFOs was initiated in early April 2014 via
email and was followed-up several times by phone. Third,
survey results were integrated with semi-structured inter-
views with key opinion leaders (KOLs) purposively se-
lected to reflect a range of factors, including expertise in
conducting research, geographic location or expertise in
awarding research funding. Transcripts were analysed
qualitatively using inductive thematic analysis [9]. The
guide investigated the themes of research activities and
funding, research priorities, duplication of research efforts
and role of the European Union. Additionally, expecta-
tions regarding outputs of funded research projects
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were investigated with surveyed RFOs and KOLs. A
constant comparative approach was used to iteratively
identify emerging themes that contribute to generate a
vision about future research funding strategies to tackle
gaps and challenges currently perceived by experts in
the field [10].
Results
The Italian case
Network of research funding organisations
The documentary analysis revealed a fragmented net-
work of biomedical research funding where central pub-
lic bodies operate alongside regional authorities and the
private sector (Fig. 1). Public sector funding is organised
via three main channels, namely the national govern-
ment, the regional governments and the ‘5 per thousand’
mechanism, which allows tax payers to donate part of
their taxable income to a selected charitable organisation
[11]. Private sources include corporate funding, as well
as non-profit organisations, either charities or founda-
tions tied to the banking sector.
Forty-six RFOs met the funding level criteria
(Additional file 1: Table S1), of which 5 (10.9%) were
national institutions (such as the Department of Health),
21 (45.6%) were regional institutions representative of as
many Regions and Autonomous Provinces in Italy, and 11
(23.9%) were banking foundations. The remaining 9
(19.6%) were research associations (e.g. Italian Association
for Cancer Research) or scientific societies (e.g. Italian So-
ciety of Cardiology). Of the invited RFOs, data were col-
lected for 26 organisations (57%), of which 14 were private
non-profit organisations and 12 were public RFOs. Three
follow-up interviews with KOLs were conducted with the
aim to solicit views and experiences of people involved in
both the conduct and funding of research in Italy. All
KOLs were experienced Principal Investigators working in
hospital settings.
Mechanisms used to distribute funding and expectations
regarding outputs
The analysis of the funding allocation process revealed
that 44% of the RFOs surveyed indicated government or
other public funding as their major source of income,
with a relatively minor role of fundraising and private
donations. Banking foundations reported financial in-
come as their primary source. Thematic analysis of KOL
interviews highlighted a related challenge with regards
to the financial problems posed by decreasing available
public funding for biomedical research. Informants also
emphasised the competition among sponsors and re-
search teams to get access to adequate level of funding,
which tends to put team leaders under pressure to se-
cure continuous funding, fostering challenges in human
resources management practices. Most RFOs reported
the funding process to be unstructured and accept un-
solicited proposals from researchers. In the view of one
KOL, these calls were often “open, to reward quality ra-
ther than steer research” (Interview #1). Only two RFOs
(8%) reported establishing priorities through a process of
consultation with other stakeholders. Additionally, there
seemed to be a tendency to value continuity with past
funding decisions.
Fig. 1 Funding for biomedical research in Italy. FFO Fondo di Finanziamento Ordinario (Fund for Ordinary Financing), FOE Fondo Ordinario per il
Finanziamento degli Enti e Istituzioni di Ricerca (Ordinary Fund for Financing of Research Institutes), PRIN Progetti di Ricerca di Interesse Nazionale
(Research Projects of National Interest), FIRB Fondo per gli Investimenti della Ricerca di Base (Fund for Investments in Basic Research), FAR Fondo
per le Agevolazioni alla Ricerca (Fund for Incentives for Research), NFP not-for-profit, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico
(Scientific Institute for Research, Hospitalisation and Healthcare), ISS Istituto Superiore di Sanità (National Institute for Health), AIFA Agenzia Italiana
del Farmaco (National Drug Agency)
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Coherently with the funding mechanisms highlighted,
most RFOs reported not having pre-defined expectations
for grant receivers. The most reported expected output
was the publication of academic articles. However, infor-
mants categorised this particular output as a propaedeu-
tic step, with the definition of impact going beyond
academic publishing.
Most of the public resources were dedicated to Italian
or Italian-based researchers and research organisations
since the aim was to strengthen national scientific basis
in order to promote effective collaboration in large inter-
national and European research initiatives.
Funding patterns towards biomedical and NCD research
In Italy, public funding is distributed from the central
government, from Regions or through the ‘5 per
thousand’ mechanism. The Ministry for Education,
University and Research organises funding through dif-
ferent channels, namely the Fondo di Finanziamento
Ordinario (General University Fund), which consisted of
€6.7 billion in 2013, mainly for permanent staff salaries
and with a minor proportion allocated for research; the
Fondo Ordinario per il Finanziamento degli Enti e
Istituzioni di Ricerca (Research Centres Fund), addressed
to research centres managed by the Ministry for
Education, University and Research itself (147 in total, of
which 10 are health related), with a funding of €1.7
billion for 2013; the Fondo per gli Investimenti della
Ricerca di Base (Supplementary Fund for Basic Research)
to finance universities and research centres working in co-
operation with industry and amounting to less than €100
million; the Fondo per le Agevolazioni alla Ricerca (Fund
for Incentives for Research) for corporate research (less
than €100 million); and Progetti di Rilevante Interesse
Nazionale (research projects of national interest). Data
for the latter funding channel are project specific, they
were analysed and categorised according to the NCDs
of interest (Fig. 2).
Regional funding per NCD could not be mapped due
to lack of data, as also noted by Compagni and Tediosi
[12]. As regards the ‘5 per thousand’ donations, data are
available for the period 2008–2011. A proportion of ap-
proximately 15% of all entities (i.e. 40 to 45 organisa-
tions from 2008 to 2011) receiving funds has not made a
report available. The remaining contributions have been
allocated to different NCD areas according to the project
titles (Fig. 3).
According to the Italian Association of Bank Foundations
and Mutual Savings, bank foundations financed scientific
and technological research with €128.3 million, equal to
14% of the total activities funded in 2013, and financing
over 1200 projects. Approximately 30% (€38.9 million, cor-
responding to 344 projects) were allocated to healthcare re-
search, which represents an area of increasing investments
(+60% compared to the previous year). Figure 4 shows the
amount of funding by banking foundations as retrieved
through the survey.
The German case
Network of research funding organisations
Public research funding in Germany is organised among
the federal government and 16 federal states (Länder).
Länder are responsible for providing higher research in-
stitutions with institutional/core funding, which is not
tied to any prerequisite or priority, but is instead deter-
mined as global budgets. However, in addition to core
funding, (public) project funding has become an import-
ant source of funding for universities and other research
performing bodies over the last years [13].
The key organisation for project-based funding is the
German Research Foundation (DFG), which is financed
by the federal government and Länder alike (58:42
share). The DFG does not have a particular research
focus and provides funds to all fields of science and hu-
manities [14].
Alongside the DFG, ministries on federal government
(and Länder) level are the second pillar in terms of pub-
lic project funding. The main ministry for federal project
funding is the ministry for education and research
(BMBF) and accounts for almost 60% of all ministry
funds. Biomedical, and therefore NCD, research is also
funded by the Ministry of Health in certain areas of min-
isterial interests, but this accounts for only 4% of all re-
search grants [13]. All ministries authorise external
institutions for distributing, coordinating and evaluating
their project funds. For health-related project funds, the
German Aerospace Centre is responsible for adminis-
tering research grants.
Private non-profit and commercial RFOs include cor-
porate funding as well as foundations. There are several
corporate RFOs of relevant size, tied to companies such
as Volkswagen or Robert Bosch, but also hundreds of
smaller non-profit foundations. However, the foundation
landscape in Germany is very fragmented, organised
around specific diseases or acknowledged gaps in
medical care or to help the family of a specific group of
patients. Its share on the overall funding on biomedical
research is not well documented, but is expected to rank
third next to public and commercial funding [15]. The
majority of identified foundations were not eligible for
inclusion because of their limited investments in NCD
research.
Within this framework, 13 RFOs were identified as eli-
gible for inclusion in our analysis (Additional file 2:
Table S2). Of these, 10 are private foundations, in most
cases linked to bigger companies. The remaining three
are public national institutions. Of the invited RFOs,
full data was collected for 30% (three public (DFG,
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German Aerospace Centre, which represents BMBF, and
Bundesministerium für Gesundheit (Federal Ministry of
Health)) and one private). Seven follow-up interviews with
KOLs were conducted with the aim to solicit views and
experiences of people involved in both the conduct and
funding of research in Germany.
Mechanisms used to distribute funding and expectations
regarding outputs
The major source of income for public RFOs are the
government and other public sources. Private founda-
tions receive their funding from company revenues and/
or through charity. Fundraising plays a minor role for
big foundations – smaller foundations rely on private
donations. Interviews with KOLs revealed the import-
ance of small foundations for bridging financial gaps
(e.g. between two bigger publicly funded projects). In
general, KOLs involved in conducting research mentioned
the increasing competition among research grants and the
time burden for researchers to write proposals and to ac-
knowledge varying deadlines, grant proposal guidelines
and other prerequisites. Some KOLs highlighted the posi-
tive effect of competition in research, provided that there
is transparency and only excellence is rewarded.
All surveyed RFOs reported establishing priorities
through a process of consultation with other stake-
holders. For example, the DFG claims having over
15,000 scientific reviewers per year for consultation [14].
Coherently with the funding mechanisms reported, most
RFOs reported having expectations, such as published
articles or reports, from grant receivers. The DFG, as
the key public funding organisation, reported having
much greater expectations, such as improvements in
(drug) therapies, increased political attention for a par-
ticular research field or even legislative changes.
Both the DFG and the ministries distribute the majority
of their projects to national research organisations, but
are expanding their involvement in international research
Fig. 2 Research projects of national interest (PRIN) funding by non-communicable disease area 2002–2012 [23]. No funding data available for 2011
Fig. 3 Non-communicable disease funding via ‘5 per thousand’ channel, 2008–2011 [24]
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funding and fellowships for young researchers going
abroad (e.g. cooperation with developing countries funded
by DFG).
Public funding patterns towards biomedical and NCD
research
In 2013, the BMBF and DFG distributed €66.5 million
(out of a total budget of €3.3 bn) and €105.2 million
(total budget of €2.7 bn), respectively, towards NCD pro-
jects (not only directed to universities, but also to other
research performing actors; Fig. 5) [13, 14]. Figure 6 de-
picts how the NCD money was shared among the five
major disease areas. The DFG had a particular focus on
cancer research, while the BMBF put a higher emphasis
on cardiovascular disease (CVD) research. Chronic re-
spiratory disease research received the lowest share of
total funding. However, all clinicians interviewed
expressed worry about the continuous trend of popular
crowding for some NCDs without surveying research
grants against the actual disease burden or foreseeable
future trends (e.g. CVD research suffers from an under-
funding of research compared to cancer, although CVDs
cause the highest disease burden). Additionally, the frag-
mentation of available funding options poses an enor-
mous administrative burden to gain an overview of
possible funding options and its required formalities.
KOLs stated that the focus has been on basic research
grants in the last years and emphasised the missing link
to applied research in the NCD field. They highlighted
the severity of translational gaps in NCD research. In
the process from ‘bench to bedside’, there are several
well-known barriers and disincentives for not completing
the full research cycle in Germany (Interview #3 and #7).
Therefore, the government started a new initiative, the so
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Fig. 5 Non-communicable disease research landscape in Germany. Dashed arrows indicate project funding flows, continuous lines symbolise core
funding. DFG Deutsche Forschungsgemeinschaft (German Research Foundation), BMG Bundesministerium für Gesundheit (Federal Ministry of Health),
BMBF Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research), DLR Deutsches Zentrum für Luft- und Raumfahrt
(German Aerospace Center), HGF Helmholtz-Gemeinschaft Deutscher Forschungszentren (The Helmholtz Association of German Research Centres),
MPG Max Plank Gesellschaft (Max Planck Society), WGL Leibniz Gemeinschaft (Leibniz Association), FhG Fraunhofer Gesellschaft (Fraunhofer Society)
Fig. 4 Projects financed by banking foundations in non-communicable diseases, total amount 2002–2013 (survey data). Thirteen research funding
organisations reported data for 2003, 2004, 2006, 2011, 2012, 2013; 14 for 2009; 16 for 2007 and 2008; 15 for 2005; and 10 for 2002
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called health research centres, which receive continuous
funding [16]. The research centres (five centres for each
NCD area plus one centre for infectious disease) put an
emphasis on translational science and are meant to bridge
several phases of NCD research while providing a longer
funding perspective. Some interviewed partners valued
these newly established networks across several layers of
the fragmented German research landscape (e.g. between
public universities and Helmholtz Association of Research
centres, which is the largest scientific organisation in
Germany) and stated that they offer a platform for consol-
idated cooperation along highly specialised research areas
(Interview #3 and #7). On the other hand, the consider-
able funding for these research centres is shared amongst
only some of the research organisations and its outcome
is yet to be seen (Interview #5 and #6).
Discussion
A varying degree of fragmentation was observed across
the two analysed research systems; the number of in-
cluded RFOs in Italy is almost four times greater than
that in Germany (Table 1). The German funding system
appears to be more concentrated than the Italian system,
where the network of actors, both public and private, is
more comprehensive, mostly due to the numerous bank-
ing foundations. In Germany, public project funding is
mainly distributed through the DFG and the ministries,
and in particular the BMBF, both of which act on a na-
tional level. Regional funding bodies are not as important
as in Italy. A comparable mechanism to the ‘5 per thou-
sand’ mechanism does not exist in Germany. Private per-
sons have to actively donate part of their income;
although private donations lead to tax breaks, only 6% of
German citizens donate into health research, compared to
39% in Italy (European Union average is 26%) [17]. Our
analysis shows that a considerable share of money for
NCD research has been donated by Italian citizens over
the last years. However, one issue of this funding mechan-
ism is the unpredictability of future funding budgets
(Fig. 3).
It appears that the majority of funding grants in Italy
and Germany is distributed without explicit research pri-
orities. In Italy, only 8% of analysed RFOs make research
investments through a process of consultation. In
Germany, the largest analysed research foundation – the
German DFG – stated that there is no explicit process
of deciding research priorities for most of their funding.
Therefore, future funding decisions should also reflect
actual societal needs (e.g. higher investments into CVD
research, since they account for 42% of all deaths in Europe
[18]). Moreover, the fragmented system and the missing
consultation process is prone for research duplication.
The international collaboration in research is still un-
derrepresented in both countries. Most funding agencies
distribute their money to national research agencies, but
are expanding their involvement in international re-
search funding (e.g. as part of the so called High-Tech
strategy in Germany) [19]. Smaller countries in Europe
tend to have a higher share of international research col-
laboration than larger countries such as Italy and
Germany [20].
KOLs from both countries shed light on the final per-
ception of the users of funds, highlighting the increasing
competition among researchers to secure continuous
funding. Furthermore, high bureaucratic barriers and the
average time it takes for research funding organisations
to decide over applications were identified as major chal-
lenges for researchers. In Germany, the importance of
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Fig. 6 Public project funding (million Euro) on non-communicable disease research in Germany in 2012
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small foundations for bridging these financial gaps were
highlighted. Another major concern is the gap between
basic and clinical research. New initiatives, such as the
establishment of the German health research centres
(one research centre per NCD) or the National Plan for
Chronic Illnesses in Italy (i.e. a plan for harmonising all
preventive and therapeutic interventions for patients
with chronic illnesses), are attempting to overcome this
particular gap, but their outcome is yet to be seen.
Due to a lack of data and difficulties to receive infor-
mation of several RFOs, many NCD research funding in-
vestments could not be mapped, especially from the
private sector (e.g. private foundations in Germany). In
Italy, however, private banking funding appears to be
much lower than money gained through public channels
such as the ‘5 per thousand mechanism’. In Germany,
total private third party funding has decreased over the
last decade and it is estimated that it accounts for less
than 10% of the total research funding at Higher Educa-
tion Institutions [15]. Public funding appears to be the
major source for research in both countries.
Limitations
This study provides an attempt to comprehensively map
the funding landscape for NCD research in two large
European countries. Despite the mixed methodologies
employed with regards to communication with RFOs
during the project, we relied on publicly available data
or on the willingness to cooperate by the RFOs. How-
ever, because of lack of reporting and data in this field,
particularly in the private sector, it is possible that
some of the RFOs active in either country were not
identified and were therefore not included in the ana-
lysis. We selected a specific framework to perform the
cross-country evaluation, taking into account the pro-
found structural differences between the two systems.
Other approaches could have been used in the com-
parison, such as an indirect way of estimating research
funding based on the analysis of research outputs (i.e.
published academic papers) [21]; however, this effort
was not immediate to apply and operationalise across
five disease areas. This analysis does not include any
measures of research outcome as bibliometric data,
and therefore no statements on the quality or impact
of research can been made on either German and
Italian research.
Conclusion
This analysis of Italian and German research funding
structures revealed substantial differences between the
two systems, making any crude statements about NCD
research in the two countries biased if not adjusted for
appropriate factors.
If the European Union wants to proceed with its
European Research Area, as declared in the Lisbon
Treaty [22], more cross-countries information about
current research system differences and their character-
istics is needed. Even with more funding available for
research efforts, we need to obtain a greater under-
standing of how and by what principles the funds are
administered by national RFOs. The particularities of
the national research landscapes in Italy and Germany
have been constant over the years, providing several
advantages and disadvantages. More coordination of
research priorities between European Union member
states on NCDs and their funding institutions is re-
quired. The current system is prone to duplicated
research efforts, fund crowding for certain diseases and
member states, and the intransparency of research re-
sults. This requires greater attention and understanding
of research system differences by politicians, RFOs,
researchers and other stakeholders.
Table 1 Cross-country comparison of non-communicable disease funding systems in Italy and Germany
Italy Germany
Identified eligible RFOs 46 13
Main research funding sources Central and regional governments, ‘5 per
thousand’ mechanism, foundations (banking)
Central government and other national
funding bodies, foundations (charity, company)
Public NCD project funding/total project
funding budget
PRIN: €4.1 mn/€100 mn (2012) DFG: €105.2 bn/€2.7 bn (2013)
‘5 per thousand’: €35mn (2011) BMBF: €66.5 bn/€3.3 bn (2013)
Public NCD funding Cancer (€37.1 mn) Cardiovascular diseases (€56.4 mn)
Cardiovascular diseases (€1.4 mn) Cancer (€55.6 mn)
Diabetes (€710 k) Mental health (€32.8 mn)
Mental health (€550 k) Diabetes (€18.9 mn)
Chronic respiratory diseases (€66 k) Chronic respiratory diseases (€7.9 mn)
BMBF Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research), DFG Deutsche Forschungsgemeinschaft (German
Research Foundation), NCD non-communicable disease, PRIN Progetti di Rilevante Interesse Nazionale (research projects of national interest), RFO research
funding organisation
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